WO2002032867A1 - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
WO2002032867A1
WO2002032867A1 PCT/GB2001/004580 GB0104580W WO0232867A1 WO 2002032867 A1 WO2002032867 A1 WO 2002032867A1 GB 0104580 W GB0104580 W GB 0104580W WO 0232867 A1 WO0232867 A1 WO 0232867A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
fluoro
trifluoromethyl
bis
Prior art date
Application number
PCT/GB2001/004580
Other languages
English (en)
French (fr)
Inventor
Giuseppe Alvaro
Romano Di Fabio
Paolo Maragni
Marsia Tampieri
Maria Elvira Tranquillini
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK04077714T priority Critical patent/DK1524266T3/da
Priority to AU9572301A priority patent/AU9572301A/xx
Priority to DE60106287T priority patent/DE60106287T2/de
Priority to BR0114637-8A priority patent/BR0114637A/pt
Priority to PL361180A priority patent/PL203071B1/pl
Priority to MXPA03003536A priority patent/MXPA03003536A/es
Priority to AT01976453T priority patent/ATE278669T1/de
Priority to IL15516501A priority patent/IL155165A0/xx
Priority to SI200130206T priority patent/SI1326832T1/xx
Priority to CA002425876A priority patent/CA2425876C/en
Priority to DK01976453T priority patent/DK1326832T3/da
Priority to HU0301459A priority patent/HU228146B1/hu
Priority to AU2001295723A priority patent/AU2001295723B2/en
Priority to EP01976453A priority patent/EP1326832B1/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to JP2002536051A priority patent/JP3940359B2/ja
Priority to KR1020037005286A priority patent/KR100847414B1/ko
Priority to NZ525091A priority patent/NZ525091A/en
Priority to US10/398,264 priority patent/US7119092B2/en
Publication of WO2002032867A1 publication Critical patent/WO2002032867A1/en
Priority to IL155165A priority patent/IL155165A/en
Priority to NO20031561A priority patent/NO324468B1/no
Priority to HK04100241A priority patent/HK1058788A1/xx
Priority to US10/994,605 priority patent/US7060702B2/en
Priority to AU2005204234A priority patent/AU2005204234B2/en
Priority to US11/358,631 priority patent/US7294630B2/en
Priority to US11/865,211 priority patent/US7648990B2/en
Priority to IL191486A priority patent/IL191486A0/en
Priority to AU2009201407A priority patent/AU2009201407B2/en
Priority to US12/630,037 priority patent/US20100081667A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Definitions

  • the present invention relates to piperidine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use.
  • the invention relates to novel compounds which are potent and specific antagonists of tachykinins, including substance P and other neurokinins.
  • WO 97/16440 describes 1-(1 ,2-disubstituted piperidinyl)-4-substituted piperazine derivatives of general formula
  • n and m are inter alia 1, p is 1 ; Q is inter alia oxygen; X is a covalent bond or a bivalent radical of formula -O-, -S-, NR 3 ; R 3 is hydrogen or a 0- _g alkyl group; R 1 is inter alia Ar 1 ; R2 may be inter alia A C ⁇ alkyl wherein Ar 2 and Ar 1 are inter alia a phenyl group which may be substituted with 1 , 2 or 3 substituents each independently selected from halo, C ⁇ alkyl, haloC 1 .
  • L may be inter alia hydrogen, C ⁇ _ ⁇ alkyl or L is a radical of formula -(CHR 4 )rC(O)YlR7 wherein r is 0,1,2,3 or 4, Y 1 is inter alia a NH or a N(C ⁇ _ ⁇ alkyl) group or Y 1 is a covalent bond and R 7 is inter alia C-
  • the compounds are antagonists of tachykinins. ⁇
  • R represents a halogen atom or a C ⁇ ]_4 alkyl group
  • R- ⁇ represents a C-j_4 alkyl group
  • R2 represents hydrogen or a C ⁇ _4 alkyl group
  • R3 represents hydrogen, or a C ⁇
  • R4 represents a trifluoromethyl group
  • R5 represents hydrogen, a C ⁇ _4 alkyl group or C(O)R 6 ;
  • R ⁇ represents C ⁇ _4 alkyl, C3 7 cycloalkyl, NH(C ⁇ _4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; and pharmaceutically acceptable salts and solvates thereof.
  • a further embodiment of the invention provides compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein
  • R represents a halogen atom or a C ⁇ _4 alkyl group
  • represents a C-j.4 alkyl group
  • R2 represents hydrogen or a C ⁇ _4 alkyl group
  • R3 represents hydrogen or a C-
  • R4 represents a trifluoromethyl group
  • R5 represents hydrogen, a C-
  • Rg represents C- ⁇ _4 alkyl;
  • m is zero or an integer from 1 to 3;
  • n is an integer from 1 to 3.
  • Suitable pharmaceutically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, succinates, tartrates, fumarates and maleates.
  • pharmaceutically acceptable organic or inorganic acids for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, succinates, tartrates, fumarates and maleates.
  • the solvates may, for example, be hydrates.
  • references hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable acid addition salts together with pharmaceutically acceptable solvates.
  • Suitable pharmaceutical acceptable salts of the compounds of general formula (I) may be obtained in a crystalline form and/or in an amorphous form or as a mixture thereof.
  • the wedge shaped bond indicates that the bond is above the plane of the paper and is referred to as ⁇ configuration.
  • the broken bond indicates that the bond is below the plane of the paper and is in the ⁇ configuration.
  • the ⁇ configuration at the 2 position corresponds to the R configuration and the ⁇ configuration at 4 position corresponds to the S configuration.
  • the ⁇ configuration at the 2 position corresponds to the S configuration and the ⁇ configuration at 4 position corresponds to the R configuration.
  • the assignment of the R or S configuration at the 2 and the 4 positions have been made according to the rules of Cahn, Ingold and Prelog , Experientia 1956,12, 81.
  • the configuration of the chiral carbons atom of the piperidine ring shown in 1a and 1b is hereinafter referred to as anti configuration and in formulae 1c and 1d as the syn configuration.
  • alkyl as used herein as a group or a part of the group refers to a straight or branched alkyl group containing from 1 to 4 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl or tert butyl.
  • halogen refers to a fluorine, chlorine, bromine or iodine atom.
  • C3..7 cycloalkyl group means a non-aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • a preferred group of compounds of formula (I) are those in which the carbon atom at the 2-position of piperidine ring is in the ⁇ configuration. Within this group, those compounds in which the carbon atom at the 4- position is in the ⁇ configuration are particularly preferred.
  • R represents halogen this is suitably chlorine or more preferably fluorine or when R is C-
  • Suitable values for R2 or R3 include hydrogen, a methyl, an ethyl or a propyl group.
  • R is preferably a halogen (e.g. fluorine) and/or a C-j_4 alkyl (e.g. methyl) group and m is preferably zero or an integer from 1 to 2.
  • halogen e.g. fluorine
  • C-j_4 alkyl e.g. methyl
  • R-j is preferably a methyl group.
  • R2 is preferably a hydrogen atom or a methyl group.
  • R3 is preferably a hydrogen atom or a methyl group.
  • R5 is preferably a hydrogen atom, methyl, isopropyl or a C(O)cyclopropyl, a C(O)CH 3 , a C(O)NHCH 3 or a C(O)N(CH 3 ) 2 group.
  • a preferred class of compounds of formula (I) are those wherein each R is independently a halogen (e.g. fluorine) or a C ⁇ _4 alkyl (e.g. methyl) group, wherein m is 0, 1 or 2. More preferably m is 1 or 2. Within this class those wherein R is at the 2 and/or 4 position in the phenyl ring are particularly preferred.
  • halogen e.g. fluorine
  • C ⁇ _4 alkyl e.g. methyl
  • a further preferred class of compounds of formula (I) is that wherein R ⁇ is methyl, R2 or R3 represent independently hydrogen or a methyl group.
  • a particularly preferred group of compounds of formula (I) is that wherein each R is independently halogen or methyl at the 2 and/or 4 position, the groups R4 are at the 3 and 5 position, R- is methyl, R2 and R3 are independently hydrogen or methyl and R5 is methyl, isopropyl or a C(O)cycIopropyl, a C(O)CH3, a C(O)NHCH3 or a C(O)N(CH3)2 group, m is 1 or 2 and n is 2.
  • Preferred compounds according to the invention are: 4-(R)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1- carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide; 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1- carboxylic acid, [1 -(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide; 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1- carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
  • the compounds of the invention are antagonists of tachykinins, including substance P and other neurokinins, both in vitro and in vivo and are thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • NKi -receptor binding affinity has been determined in vitro by the compounds' ability to displace [3H] - substance P (SP) from recombinant human NK-j receptors expressed in Chinese Hamster Ovary (CHO) cell membranes.
  • SP substance P
  • CHO cell membranes were prepared by using a modification of the method described by Dam T and Quirion R (Peptides, 7:855-864, 1986). Thus ligand binding was performed in 0.4 ml of 50 mM HEPES, pH 7.4, containing 3 mM nCl2, 0.02% BSA, 0.5 nM [ 3 HjSubstance P (30 ⁇ 56 Ci/mmol, Amersham), a final membrane concentration of 25 ⁇ g of protein/ml, and the test compounds. The incubation proceeded at room temperature for 40 min.. Non-specific binding was determined using excess of Substance P (1 ⁇ M) and represents about 6% of the total binding. Compounds of the invention were further characterised in a functional assay for the determination of their inhibitory effect.
  • CDP-DAG cytidinediphosphodiacylglycerol
  • PLC phospholipase C
  • the action of the compounds of the invention at the NK-j receptor may be determined by using conventional tests.
  • the ability to penetrate the central nervous system and to bind at the NKi receptor was demonstrated in vivo by their inhibitory effect on the change in the behaviour induced by intracerebroventricular applied substance P in the gerbil, according to the gerbil foot tapping model as described by Rupniak & Williams, Eur. J. of Pharmacol., 1994,.
  • Compounds of the invention are useful in the treatment of CNS disorders.
  • they are useful in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders.
  • Major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood.
  • Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.
  • Compounds of the invention are useful as analgesics.
  • traumatic pain such as postoperative pain
  • traumatic avulsion pain such as brachial plexus
  • chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis
  • neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain
  • various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain
  • Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadianrudic disorders.
  • Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified.
  • compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.
  • Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine or amphetamine- related drugs (e.g dextroamphetamine, methylamphetamine) addiction or a combination thereof.
  • Compounds of the invention are also useful as anti-inflammatory agents.
  • Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.
  • Emesis i.e. nausea, retching and vomiting.
  • Emesis includes acute emesis, delayed emesis and anticipatory emesis.
  • the compounds of the invention are useful in the treatment of emesis however induced.
  • emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g.
  • cytarabine methotrexate and 5- fluorouracil
  • vinca alkaloids e.g. etoposide, vinblastine and vincristine
  • others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof
  • radiation sickness e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g.
  • gastritis or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intercranial pressure; decreased intercranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.
  • Compounds of the invention are also useful in the treatment of gastrointestinal disorders such as irritable bowel syndrome; skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.
  • gastrointestinal disorders such as irritable bowel syndrome
  • skin disorders such as psoriasis, pruritis and sunburn
  • vasospastic diseases such as angina, vascular headache and Reynaud's disease
  • cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrhage
  • Compounds of the invention are of particular use in the treatment of depressive states, in the treatment of anxiety and of panic disorders.
  • Depressive states include major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, dysthymic disorder with early or late onset and with or without atypical features, neurotic depression and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type.
  • Compounds of the invention may be administered in combination with other active substances such as 5HT3 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants or dopaminergic antidepressants.
  • active substances such as 5HT3 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants or dopaminergic antidepressants.
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron and metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine and metoclopramide.
  • Suitable SSRI which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline and zimeldine.
  • Suitable SNRI which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations) or sequentially.
  • the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.
  • a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins, including subs.tance P and other neurokinins.
  • a method for the treatment of a mammal including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins, comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route.
  • a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route.
  • Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non- aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p- hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • composition may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi- dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • a proposed dose of the compounds of the invention is 1 to about 1000mg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.
  • a piperazine derivative (III) in an aprotic solvent such as dichloroethane and in the presence of a, suitable metal reducing agent such as sodium borohydride or sodium triacetoxyborohydride.
  • reaction conveniently takes place in an aprotic solvent such as a hydrocarbon, a halohydrocarbon such as dichloromethane or an ether such as tetrahydrofuran optionally in the presence of a base such as a tertiary amine e.g. diisopropylethylamine.
  • aprotic solvent such as a hydrocarbon, a halohydrocarbon such as dichloromethane or an ether such as tetrahydrofuran optionally in the presence of a base such as a tertiary amine e.g. diisopropylethylamine.
  • a compound formula (I) as a salt for example a pharmaceutically acceptable salt
  • this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate amount of suitable acid and in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tetrahydrofuran).
  • a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tetrahydrofuran).
  • Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compounds of formula (I) using conventional methods.
  • the compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent to give the corresponding solvates.
  • enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates using any of the general processes described herein.
  • the required enantiomer may be prepared by the corresponding a chiral piperidin-4-one of formula (IV) using the process described above for preparing compounds of formula (I) from compounds (IV)., followed by separation of the diastereomeric mixture of a compound of formula(l) using conventional procedure.
  • the chiral compounds (IV) may be prepared from the corresponding racemic compound (IV) using conventional procedures such as salt formation with a suitable optically active acid, separating the resultant diastereoisomeric salts by conventional means e.g. chromatography and crystallisation followed by hydrolysis of the diastereoisomeric salts.
  • a suitable optically active acid for use in the process is L(+)mandelic acid.
  • the chiral compound (IV) may be prepared using Comins reaction as described in Journal American Chemical Society 1994,116, 4719-4728, followed by reduction of 2,3 dihydro-1H-pyridin-4-one derivative to piperidin-4-one derivative.
  • the reduction may be effected using hydrogen and metal catalyst e.g. palladium on a suitable support e.g. carbon or alumina.
  • the reaction is carried out in a solvent such as ester e.g. ethyl acetate.
  • the enantiomers of the compound of formula (I) may be prepared by reaction of a chiral amine (VI) using any of the processes described above for preparing compounds of formula (I) from amine (V).
  • the chiral amine (III) may be prepared from the corresponding racemic amine (III) using any conventional procedures such as salt formation with a suitable optically active acid.
  • IR Infrared spectra
  • Isopropanoyl chloride (112 ⁇ L) was added to a mixture of N-tert- butoxycarbonylpiperazine (200 mg) and an excess of potassium carbonate in anhydrous DCM (10 mL) under a nitrogen atmosphere. The mixture was stirred at r.t. for 18 hours, then it was filtered off from inorganics. The organic phase was diluted with Et2O (20 mL) and washed with 1N hydrochloric acid solution (10 mL). The aqueous phase was made basic with 1N sodium hydroxide solution and extracted twice with DCM.
  • the compound is isolated in a crystalline form.
  • Trifluoroacetic acid (1 mL) was added drop-wise at 0°C to a solution of compound 2 (48 mg) in dry DCM (3 mL). The solution was stirred for 1 hour at the same temperature and for 1 hour at r.t.. Then the solvent was removed in vacuo and the crude dissolved in AcOEt (5 mL). The resulting solution was washed with a saturated potassium carbonate solution and dried.
  • Example 14 4-(S)-[4-(2-Methyl-propanoyl)-piperazin-1-yl]-2-(R)-(4-fluoro-2-methyl- pheny l)-piperidine-1 -carboxylic acid, [1 -(R)-(3,5-bis-trifluoromethy I- phenyl)-ethyl]-methylamide hydrochloride
  • TEA (74.6 ⁇ L) and triphosgene (13.2 mg) were added to a solution of example 17 (50 mg) in anhydrous DCM (2 mL) under a nitrogen atmosphere.
  • the solution was stirred at 23°C for 2 hours, then DIPEA (31.9 ⁇ L) and methylamine (2M solution in THF - 49 ⁇ L) were added.
  • the mixture was stirred at 23°C for 18 hour, then poured into 1M hydrochloric acid solution (10 mL) and extracted with AcOEt (2 x 20 mL).
  • the active ingredient is blended with the other excipients.
  • the blend can be used to fill gelatin capsules or compressed to form tablets using appropriate punches.
  • the tablets can be coated using conventional techniques and coatings.
  • Magnesium Stearate 1.5mg The active ingredient is blended with lactose, microcrystalline cellulose and part of the croscarmellose sodium.
  • the blend is granulated with povidone after dispersing in a suitable solvent (i.e. water).
  • a suitable solvent i.e. water
  • the granule, after drying and comminution is blended with the remaining excipients.
  • the blend can be compressed using appropriate punches and the tablets coated using conventional techniques and coatings.
  • the formulation may be packed in glass ampoules or vials and syringes with a rubber stopper and a plastic/metal overseal (vials only).
  • Active ingredient 2-60 mg/ml Infusion solution (NaCI 0.9% or 5% dextrose) qs to 100ml
  • the formulation may be packed in glass vials or plastic bag.
  • the affinity of the compound of the invention for NK1 receptor was determined using the NK-
  • SP displace [3H] - substance P
  • the affinity values are expressed as negative logarithm of the inhibition constant (Ki) of displacer ligands (pKi).
  • the ability of the compounds of the invention to penetrate the central nervous system and to bind at the nk1 receptor may be determined using the gerbill foot tapping model as described by Rupniak & Williams, Eur. Jour, of Pharmacol., 1994.
  • an NK1 agonist e.g. delta-Aminovaleryl 6 [Pro 9 ,Me-Leu 10 ]-substance P (7-11)
  • 3pmol in 5 ⁇ L icv was infused directly in the cerebral ventricules of the animals.
  • the duration of hind foot tapping induced by the NK1 agonist e.g. delta-AminovaIeryl 6 [Pro 9 ,Me-Leu 10 ]-substance P (7-11)
  • the dose of the test compound required to inhibit by 50% the tapping induced by the NK1 agonist e.g. delta-Aminovaleryl 6 [Pro 9 ,Me-Leu 10 ]-substance P (7-11) expressed as mg/kg is referred as the ED50 values.
  • the compounds may be administered subcutaneously or intraperitoneally.
PCT/GB2001/004580 2000-10-17 2001-10-12 Chemical compounds WO2002032867A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
JP2002536051A JP3940359B2 (ja) 2000-10-17 2001-10-12 化合物
AU9572301A AU9572301A (en) 2000-10-17 2001-10-12 Chemical compounds
BR0114637-8A BR0114637A (pt) 2000-10-17 2001-10-12 Compostos quìmicos
PL361180A PL203071B1 (pl) 2000-10-17 2001-10-12 Pochodne piperydyny, ich zastosowania, zawierająca je kompozycja farmaceutyczna oraz sposób ich wytwarzania
MXPA03003536A MXPA03003536A (es) 2000-10-17 2001-10-12 Compuestos quimicos.
AT01976453T ATE278669T1 (de) 2000-10-17 2001-10-12 Chemische verbindungen
IL15516501A IL155165A0 (en) 2000-10-17 2001-10-12 Chemical compounds
SI200130206T SI1326832T1 (en) 2000-10-17 2001-10-12 Chemical compounds
CA002425876A CA2425876C (en) 2000-10-17 2001-10-12 Piperidine derivatives as antagonists of tachykinins
DK01976453T DK1326832T3 (da) 2000-10-17 2001-10-12 Kemiske forbindelser
HU0301459A HU228146B1 (en) 2000-10-17 2001-10-12 Chemical compounds process for producing them and pharmaceutical compositions containing them
AU2001295723A AU2001295723B2 (en) 2000-10-17 2001-10-12 Chemical compounds
EP01976453A EP1326832B1 (en) 2000-10-17 2001-10-12 Chemical compounds
DK04077714T DK1524266T3 (da) 2000-10-17 2001-10-12 Farmaceutisk sammensætning
DE60106287T DE60106287T2 (de) 2000-10-17 2001-10-12 Chemische verbindungen
KR1020037005286A KR100847414B1 (ko) 2000-10-17 2001-10-12 피페리딘 화합물
NZ525091A NZ525091A (en) 2000-10-17 2001-10-12 Piperazinyl susbtituted piperidinyl compounds as antagonists of tachykinins
US10/398,264 US7119092B2 (en) 2000-10-17 2001-10-12 Chemical compounds
IL155165A IL155165A (en) 2000-10-17 2003-03-31 History of piperidine, process for their preparation, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of conditions related to tequinin
NO20031561A NO324468B1 (no) 2000-10-17 2003-04-07 Kjemiske forbindelser
HK04100241A HK1058788A1 (en) 2000-10-17 2004-01-13 Chemical compounds.
US10/994,605 US7060702B2 (en) 2000-10-17 2004-11-22 Chemical compounds
AU2005204234A AU2005204234B2 (en) 2000-10-17 2005-08-24 Chemical Compounds
US11/358,631 US7294630B2 (en) 2000-10-17 2006-02-21 Piperazinyl piperidine tachykinin antagonists
US11/865,211 US7648990B2 (en) 2000-10-17 2007-10-01 Chemical compounds
IL191486A IL191486A0 (en) 2000-10-17 2008-05-15 Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions
AU2009201407A AU2009201407B2 (en) 2000-10-17 2009-04-09 Chemical compounds
US12/630,037 US20100081667A1 (en) 2000-10-17 2009-12-03 Chemical Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0025354.2 2000-10-17
GBGB0025354.2A GB0025354D0 (en) 2000-10-17 2000-10-17 Chemical compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10398264 A-371-Of-International 2001-10-12
US10/994,605 Continuation US7060702B2 (en) 2000-10-17 2004-11-22 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2002032867A1 true WO2002032867A1 (en) 2002-04-25

Family

ID=9901397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004580 WO2002032867A1 (en) 2000-10-17 2001-10-12 Chemical compounds

Country Status (29)

Country Link
US (5) US7119092B2 (US07648990-20100119-C00002.png)
EP (4) EP1326832B1 (US07648990-20100119-C00002.png)
JP (1) JP3940359B2 (US07648990-20100119-C00002.png)
KR (1) KR100847414B1 (US07648990-20100119-C00002.png)
CN (1) CN1231468C (US07648990-20100119-C00002.png)
AR (1) AR034268A1 (US07648990-20100119-C00002.png)
AT (3) ATE355271T1 (US07648990-20100119-C00002.png)
AU (4) AU9572301A (US07648990-20100119-C00002.png)
BR (1) BR0114637A (US07648990-20100119-C00002.png)
CA (1) CA2425876C (US07648990-20100119-C00002.png)
CY (1) CY1107634T1 (US07648990-20100119-C00002.png)
CZ (1) CZ299824B6 (US07648990-20100119-C00002.png)
DE (3) DE60127002T2 (US07648990-20100119-C00002.png)
DK (2) DK1524266T3 (US07648990-20100119-C00002.png)
ES (3) ES2346108T3 (US07648990-20100119-C00002.png)
GB (1) GB0025354D0 (US07648990-20100119-C00002.png)
HK (2) HK1058788A1 (US07648990-20100119-C00002.png)
HU (1) HU228146B1 (US07648990-20100119-C00002.png)
IL (3) IL155165A0 (US07648990-20100119-C00002.png)
MX (1) MXPA03003536A (US07648990-20100119-C00002.png)
MY (1) MY124957A (US07648990-20100119-C00002.png)
NO (1) NO324468B1 (US07648990-20100119-C00002.png)
NZ (1) NZ525091A (US07648990-20100119-C00002.png)
PL (1) PL203071B1 (US07648990-20100119-C00002.png)
PT (2) PT1524266E (US07648990-20100119-C00002.png)
SI (2) SI1326832T1 (US07648990-20100119-C00002.png)
TW (1) TWI299730B (US07648990-20100119-C00002.png)
WO (1) WO2002032867A1 (US07648990-20100119-C00002.png)
ZA (1) ZA200302801B (US07648990-20100119-C00002.png)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066621A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives and their use as antagonists of tachykinins
WO2003066635A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives
WO2003066589A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
WO2003099787A1 (en) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Novel piperidine compound
WO2004022521A1 (en) * 2002-09-06 2004-03-18 Central Glass Company, Limited Optically active 1-(fluoro-,trifluoromethyl-or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivatives and process for producing same
WO2004056805A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
WO2004056364A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056800A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
WO2004056799A3 (en) * 2002-12-23 2004-08-12 Janssen Pharmaceutica Nv Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087685A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
FR2853648A1 (fr) * 2003-04-11 2004-10-15 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004089901A2 (en) * 2003-03-31 2004-10-21 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004091616A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
WO2004110451A1 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
WO2004110996A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US6951861B1 (en) 1999-10-07 2005-10-04 Smithkline Beechan Corporation Chemical compounds
WO2005097774A1 (en) * 2004-04-08 2005-10-20 Janssen Pharmaceutica N.V. Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
US7060702B2 (en) 2000-10-17 2006-06-13 Smithkline Beecham Corporation Chemical compounds
WO2006061233A1 (en) * 2004-12-08 2006-06-15 Glaxo Group Limited The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide
WO2007009778A1 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited Piperidine carboxamide derivate suitable as tachykinin receptor antagonist
WO2007009777A1 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited Chemical compounds
WO2007009758A2 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist
US7196077B2 (en) 2001-04-05 2007-03-27 Glaxo Group Limited Tachykinin antagonists
US7214680B2 (en) 2001-08-14 2007-05-08 Glaxo Group Limited 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
WO2008001719A1 (fr) 2006-06-30 2008-01-03 Central Glass Company, Limited Procédé de production d'un dérivé optiquement actif de 1-(phényle à substitution fluoro, trifluorométhyle ou trifluorométhoxy)alkylamine n-monoalkyle
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
WO2010007032A1 (en) * 2008-07-14 2010-01-21 Glaxo Wellcome Manufacturing Pte Ltd Piperidine based ureas as nk1 antagonists
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
WO2013124286A1 (en) 2012-02-22 2013-08-29 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
WO2009035652A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
EA201992414A1 (ru) 2017-04-10 2020-03-16 Чейс Терапьютикс Корпорейшн Комбинация nk1-антагониста и способ лечения синуклеинопатий
IL271464B1 (en) 2017-06-30 2024-04-01 Chase Therapeutics Corp NK-1 antagonist preparations and methods for use in the treatment of depression
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0655442A1 (en) * 1993-11-29 1995-05-31 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as Tachykinin antagonists
WO1997016440A1 (en) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536020A (en) * 1894-04-09 1895-03-19 Washing or bathing apparatus
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
US5334387A (en) * 1993-02-23 1994-08-02 Colgate-Palmolive Company Topical composition comprising mono and dialkyl phosphates with a cosurfactant
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
ATE169603T1 (de) 1993-11-26 1998-08-15 Rockwool Mineralwolle Verfahren zum herstellen einer schmelze für die mineralfaserherstellung
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
EP0721941A4 (en) 1994-07-15 1996-09-25 Meiji Seika Co NOVEL COMPOUNDS HAVING AN INHIBITING EFFECT ON PLATELET AGGREGATION
AU3085895A (en) 1994-07-26 1996-02-22 Sankyo Company Limited N-phenylated amide and urea derivatives
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
DK0783490T3 (da) 1994-09-30 2002-05-13 Novartis Ag 1-Acyl-4-alifatiske aminopiperidinforbindelser
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2207618A1 (en) 1994-12-23 1996-07-04 Helmut Pieper Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
CA2249604A1 (en) 1996-04-03 1997-10-09 Theresa M. Williams Inhibitors of farnesyl-protein transferase
CA2249599A1 (en) 1996-04-03 1997-10-09 Dong D. Wei Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507579A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
AU731672B2 (en) 1996-12-02 2001-04-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating bipolar disorders
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
WO1999009985A1 (en) 1997-08-27 1999-03-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU751950B2 (en) 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6253732B1 (en) * 1999-11-11 2001-07-03 Ford Global Technologies, Inc. Electronic throttle return mechanism with a two-spring and two-lever default mechanism
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0655442A1 (en) * 1993-11-29 1995-05-31 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as Tachykinin antagonists
WO1997016440A1 (en) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345041B2 (en) 1999-10-07 2008-03-18 Smithkline Beecham Corporation Chemical compounds
US6951861B1 (en) 1999-10-07 2005-10-04 Smithkline Beechan Corporation Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
US7071196B2 (en) 1999-10-07 2006-07-04 Smithkline Beecham Croporation Chemical compounds
US7625904B2 (en) 1999-10-07 2009-12-01 Smithkline Beecham Corporation Methods for the treatment of sleep disorders
US7060702B2 (en) 2000-10-17 2006-06-13 Smithkline Beecham Corporation Chemical compounds
US7119092B2 (en) 2000-10-17 2006-10-10 Smithkline Beecham Corporation Chemical compounds
US7648990B2 (en) 2000-10-17 2010-01-19 Glaxosmithkline Llc Chemical compounds
US7294630B2 (en) 2000-10-17 2007-11-13 Smithkline Beecham Corporation Piperazinyl piperidine tachykinin antagonists
US7196077B2 (en) 2001-04-05 2007-03-27 Glaxo Group Limited Tachykinin antagonists
US7214680B2 (en) 2001-08-14 2007-05-08 Glaxo Group Limited 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
US7652012B2 (en) 2002-02-08 2010-01-26 Glaxo Group Limited 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof
US7189713B2 (en) 2002-02-08 2007-03-13 Glaxo Group Limited Piperidine derivatives
WO2003066635A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives
WO2003066589A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
AU2003205753B2 (en) * 2002-02-08 2010-01-07 Nerre Therapeutics Limited Piperdine derivatives
AU2003205753B8 (en) * 2002-02-08 2010-02-18 Nerre Therapeutics Limited Piperdine derivatives
US7276509B2 (en) 2002-02-08 2007-10-02 Glaxo Group Limited Piperidine derivatives and their use as antagonists of tachykinins
WO2003066621A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives and their use as antagonists of tachykinins
AU2003205753B9 (en) * 2002-02-08 2010-03-04 Nerre Therapeutics Limited Piperdine derivatives
KR100722354B1 (ko) * 2002-05-29 2007-05-29 다나베 세이야꾸 가부시키가이샤 신규 피페리딘 화합물
WO2003099787A1 (en) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Novel piperidine compound
US7619092B2 (en) 2002-05-29 2009-11-17 Mitsubishi Tanabe Pharma Corporation Piperidine compounds
WO2004022521A1 (en) * 2002-09-06 2004-03-18 Central Glass Company, Limited Optically active 1-(fluoro-,trifluoromethyl-or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivatives and process for producing same
US7186865B2 (en) 2002-09-06 2007-03-06 Central Glass Company, Limited Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same
US7368609B2 (en) 2002-09-06 2008-05-06 Central Glass Company, Limited Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same
CN100417636C (zh) * 2002-09-06 2008-09-10 中央硝子株式会社 光学活性的1-(氟-、三氟甲基-或三氟甲氧基-取代的苯基)烷基胺n-单烷基衍生物及其制备方法
EA008774B1 (ru) * 2002-12-23 2007-08-31 Янссен Фармацевтика Н.В. Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-илпиперазина и их применение в качестве антагонистов нейрокинина
JP4660199B2 (ja) * 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
JP2006514027A (ja) * 2002-12-23 2006-04-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−ピロリジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
HRP20050556B1 (hr) * 2002-12-23 2014-03-28 Janssen Pharmaceutica N.V. Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin
HRP20050554B1 (hr) * 2002-12-23 2014-02-28 Janssen Pharmaceutica N.V. Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista
JP4746878B2 (ja) * 2002-12-23 2011-08-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−ピロリジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
JP2006512349A (ja) * 2002-12-23 2006-04-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
JP2006512348A (ja) * 2002-12-23 2006-04-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−３−イル−４−ピペリジン−４−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
JP2006512350A (ja) * 2002-12-23 2006-04-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換４−（４−ピペリジン−４−イル−ピペラジン−１−イル）−アゼパン誘導体およびそれらのニューロキニン拮抗薬としての使用
KR101049075B1 (ko) 2002-12-23 2011-07-15 얀센 파마슈티카 엔.브이. 치환된 1-피페리딘-3-일-4-피페리딘-4-일-피페라진 유도체및 그의 뉴로키닌 길항제로서의 용도
KR101049073B1 (ko) 2002-12-23 2011-07-15 얀센 파마슈티카 엔.브이. 치환된 1-피페리딘-4-일-4-피롤리딘-3-일-피페라진 유도체및 그의 뉴로키닌 길항제로서의 용도
JP4660198B2 (ja) * 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−３−イル−４−ピペリジン−４−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7795261B2 (en) 2002-12-23 2010-09-14 Janssen Pharmaceutica Nv Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056805A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
WO2004056364A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
EA009078B1 (ru) * 2002-12-23 2007-10-26 Янссен Фармацевтика Н. В. Замещенные производные 1-пиперидин-4-ил-4-пирролидин-3-илпиперазина и их применение в качестве антагонистов нейрокининов
WO2004056800A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056799A3 (en) * 2002-12-23 2004-08-12 Janssen Pharmaceutica Nv Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7572786B2 (en) 2002-12-23 2009-08-11 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
AU2003300578B2 (en) * 2002-12-23 2009-06-04 Janssen Pharmaceutica N.V. Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
US7514424B2 (en) 2002-12-23 2009-04-07 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004067093A3 (en) * 2003-01-27 2004-10-28 Glaxo Group Ltd Nk1 receptor antagonists for the treatment of functional dyspepsia
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
US7262197B2 (en) 2003-03-31 2007-08-28 Janssen Pharmaceutica, N.V Phospholipase C inhibitors for use in treating inflammatory disorders
WO2004089901A2 (en) * 2003-03-31 2004-10-21 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087685A3 (en) * 2003-03-31 2004-12-16 Janssen Pharmaceutica Nv Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087685A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004089901A3 (en) * 2003-03-31 2004-12-09 Janssen Pharmaceutica Nv Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087654A3 (en) * 2003-03-31 2005-01-27 Janssen Pharmaceutica Nv Phospholipase c inhibitors for use in treating inflammatory disorders
FR2853648A1 (fr) * 2003-04-11 2004-10-15 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004091616A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
WO2004110451A1 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
WO2004110996A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
JP2007532516A (ja) * 2004-04-08 2007-11-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換４−アルキル−および４−アルカノイル−ピペリジン誘導体およびそれらのニューロキニンアンタゴニストとしての使用
WO2005097774A1 (en) * 2004-04-08 2005-10-20 Janssen Pharmaceutica N.V. Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
EA010312B1 (ru) * 2004-04-08 2008-08-29 Янссен Фармацевтика Н.В. Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
WO2006061233A1 (en) * 2004-12-08 2006-06-15 Glaxo Group Limited The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
WO2007009758A2 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist
WO2007009758A3 (en) * 2005-07-18 2007-04-19 Glaxo Group Ltd 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist
WO2007009777A1 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited Chemical compounds
WO2007009778A1 (en) * 2005-07-18 2007-01-25 Glaxo Group Limited Piperidine carboxamide derivate suitable as tachykinin receptor antagonist
WO2008001719A1 (fr) 2006-06-30 2008-01-03 Central Glass Company, Limited Procédé de production d'un dérivé optiquement actif de 1-(phényle à substitution fluoro, trifluorométhyle ou trifluorométhoxy)alkylamine n-monoalkyle
US7985880B2 (en) 2006-06-30 2011-07-26 Central Glass Company, Limited Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl) alkylamine N-monoalkyl derivative
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
WO2010007032A1 (en) * 2008-07-14 2010-01-21 Glaxo Wellcome Manufacturing Pte Ltd Piperidine based ureas as nk1 antagonists
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
WO2013124286A1 (en) 2012-02-22 2013-08-29 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
US9181259B2 (en) 2012-02-22 2015-11-10 Leo Pharma A/S Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
WO2015024878A1 (en) 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii

Also Published As

Publication number Publication date
EP1752449A1 (en) 2007-02-14
CY1107634T1 (el) 2013-04-18
GB0025354D0 (en) 2000-11-29
JP3940359B2 (ja) 2007-07-04
EP1524266B1 (en) 2007-02-28
AU2001295723B2 (en) 2005-05-26
US20060142302A1 (en) 2006-06-29
SI1524266T1 (sl) 2007-08-31
CA2425876C (en) 2009-07-07
ZA200302801B (en) 2004-04-21
DE60106287T2 (de) 2006-02-23
US20040014770A1 (en) 2004-01-22
EP1921064B1 (en) 2010-05-19
PT1524266E (pt) 2007-05-31
MXPA03003536A (es) 2003-08-07
CN1231468C (zh) 2005-12-14
DK1326832T3 (da) 2005-01-31
CN1483025A (zh) 2004-03-17
BR0114637A (pt) 2003-09-30
TWI299730B (en) 2008-08-11
US20080021041A1 (en) 2008-01-24
ES2227287T3 (es) 2005-04-01
ATE278669T1 (de) 2004-10-15
US7294630B2 (en) 2007-11-13
AU2005204234B2 (en) 2009-05-07
PL361180A1 (en) 2004-09-20
EP1921064A1 (en) 2008-05-14
ATE355271T1 (de) 2006-03-15
KR20030036932A (ko) 2003-05-09
HK1058788A1 (en) 2004-06-04
SI1326832T1 (en) 2005-02-28
US7060702B2 (en) 2006-06-13
NO20031561D0 (no) 2003-04-07
HUP0301459A2 (en) 2006-09-28
AU2005204234A1 (en) 2005-09-15
PT1326832E (pt) 2005-01-31
EP1524266A1 (en) 2005-04-20
AU2009201407A1 (en) 2009-05-07
PL203071B1 (pl) 2009-08-31
US7648990B2 (en) 2010-01-19
DE60142197D1 (de) 2010-07-01
AU9572301A (en) 2002-04-29
ATE468324T1 (de) 2010-06-15
DK1524266T3 (da) 2007-06-25
IL155165A0 (en) 2003-10-31
NO20031561L (no) 2003-06-14
IL155165A (en) 2008-11-26
HU228146B1 (en) 2012-12-28
NZ525091A (en) 2005-04-29
US7119092B2 (en) 2006-10-10
ES2282794T3 (es) 2007-10-16
IL191486A0 (en) 2008-11-03
ES2346108T3 (es) 2010-10-08
DE60127002D1 (de) 2007-04-12
AU2009201407B2 (en) 2011-12-15
US20100081667A1 (en) 2010-04-01
EP1326832B1 (en) 2004-10-06
CZ299824B6 (cs) 2008-12-03
DE60106287D1 (de) 2004-11-11
HK1075889A1 (en) 2005-12-30
EP1326832A1 (en) 2003-07-16
CA2425876A1 (en) 2002-04-25
JP2004511544A (ja) 2004-04-15
MY124957A (en) 2006-07-31
HUP0301459A3 (en) 2007-11-28
US20050137208A1 (en) 2005-06-23
DE60127002T2 (de) 2007-10-31
NO324468B1 (no) 2007-10-22
AR034268A1 (es) 2004-02-18
CZ20031082A3 (cs) 2004-08-18
KR100847414B1 (ko) 2008-07-18

Similar Documents

Publication Publication Date Title
EP1326832B1 (en) Chemical compounds
AU2001295723A1 (en) Chemical compounds
EP1218359B1 (en) Piperazine compounds as tachykinins antagonists
EP1472243A1 (en) Piperidine derivatives and their use as antagonists of tachykinins
US20070135414A1 (en) Tachykinin Antagonists
US7482365B2 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 155165

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 525091

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001295723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/02801

Country of ref document: ZA

Ref document number: 200302801

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2425876

Country of ref document: CA

Ref document number: 1020037005286

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 03032395A

Country of ref document: CO

Ref document number: PV2003-1082

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001976453

Country of ref document: EP

Ref document number: 2002536051

Country of ref document: JP

Ref document number: 018175325

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003536

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1020037005286

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001976453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10398264

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1082

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001976453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 525091

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525091

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001295723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 191486

Country of ref document: IL